A bivalent inactivated influenza vaccine incorporating epitope-optimized surface proteins confers cross-protective immunity against H9N2 influenza virus
A bivalent chimeric inactivated vaccine, designated cHANA, is developed by combining two individually rescued chimeric inactivated viruses, cHANA1 and cHANA2, by combining two individually rescued chimeric inactivated viruses to eliciting more potent cross-reactive antibody responses and T cell immunity in mice.